IRIS
IZZO, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.631
AS - Asia 2.627
NA - Nord America 2.580
SA - Sud America 914
AF - Africa 77
OC - Oceania 4
Totale 8.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.335
SG - Singapore 1.209
IT - Italia 942
RU - Federazione Russa 846
BR - Brasile 676
VN - Vietnam 485
CN - Cina 473
HK - Hong Kong 174
MX - Messico 159
DE - Germania 151
UA - Ucraina 142
NL - Olanda 115
FR - Francia 114
FI - Finlandia 86
GB - Regno Unito 66
CO - Colombia 62
CA - Canada 55
IN - India 55
JP - Giappone 55
EC - Ecuador 47
IE - Irlanda 39
AR - Argentina 38
ES - Italia 31
KR - Corea 28
PE - Perù 28
BO - Bolivia 25
ZA - Sudafrica 25
BD - Bangladesh 24
IQ - Iraq 21
PH - Filippine 20
CL - Cile 19
CI - Costa d'Avorio 18
SE - Svezia 18
PL - Polonia 13
AT - Austria 12
PK - Pakistan 12
TH - Thailandia 11
CH - Svizzera 10
ID - Indonesia 10
TR - Turchia 10
VE - Venezuela 10
HN - Honduras 7
ET - Etiopia 6
HR - Croazia 5
KE - Kenya 5
LV - Lettonia 5
MY - Malesia 5
PT - Portogallo 5
PY - Paraguay 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
AL - Albania 4
BE - Belgio 4
BG - Bulgaria 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
MA - Marocco 4
TW - Taiwan 4
EG - Egitto 3
GE - Georgia 3
IR - Iran 3
JM - Giamaica 3
JO - Giordania 3
LT - Lituania 3
RO - Romania 3
SC - Seychelles 3
SN - Senegal 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BW - Botswana 2
CU - Cuba 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GA - Gabon 2
LB - Libano 2
LU - Lussemburgo 2
ML - Mali 2
NI - Nicaragua 2
PA - Panama 2
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
CV - Capo Verde 1
DM - Dominica 1
EE - Estonia 1
GF - Guiana Francese 1
GT - Guatemala 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LY - Libia 1
NC - Nuova Caledonia 1
NG - Nigeria 1
Totale 8.824
Salva come PNG Salva come JPEG
Città #
Singapore 548
San Jose 382
Moscow 229
Ashburn 201
Chandler 176
Hong Kong 171
Beijing 158
Ho Chi Minh City 130
Naples 112
Amsterdam 103
Hanoi 99
Hefei 91
Napoli 80
The Dalles 77
Los Angeles 71
Jacksonville 69
Santa Clara 66
Lauterbourg 56
Rome 54
Millbury 52
Munich 51
Tokyo 50
São Paulo 45
Princeton 44
Milan 40
Boston 37
New York 36
Buffalo 29
Nanjing 28
Da Nang 25
Turku 25
Des Moines 24
Lima 23
Ottawa 23
Quito 23
Frankfurt am Main 21
Medellín 21
Mexico 21
Redondo Beach 21
Haiphong 20
Woodbridge 20
Wilmington 18
Brasília 17
Chennai 17
Council Bluffs 17
La Paz 17
Seoul 17
Brooklyn 16
Dallas 16
Poplar 16
Seattle 16
Bogotá 15
Santiago 15
Denver 14
Helsinki 14
Orem 14
Montreal 13
Warsaw 13
Chicago 12
Dong Ket 12
Shenyang 12
Bari 11
Cuenca 11
Falls Church 11
Houston 11
Johannesburg 11
Nuremberg 11
Salvador 11
Caserta 10
Lawrence 10
London 10
Salerno 10
Fortaleza 9
Mexico City 9
Belo Horizonte 8
Buenos Aires 8
Hebei 8
Nanchang 8
Atlanta 7
Biên Hòa 7
Can Tho 7
Florence 7
Genova 7
Manaus 7
Mumbai 7
Ninh Bình 7
Rio de Janeiro 7
Tijuana 7
Toronto 7
Vienna 7
Bologna 6
Kronberg 6
Madrid 6
Monterrey 6
New Delhi 6
Palmi 6
Veracruz 6
Addis Ababa 5
Ankara 5
Brescia 5
Totale 4.161
Salva come PNG Salva come JPEG
Nome #
Leucemia Mieloide Cronica 1.425
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 425
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 212
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 176
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 169
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 168
Laboratory medicine: health evaluation in elite athletes 165
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 165
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 162
Spleen is the dark side of essential Thrombocitemia 158
RISPOSTA EMATOLOGICA AL TRATTAMENTO CON LENALIDOMIDE IN UNA PAZIENTE AFFETTA DA TROMBOCITEMIA ESSENZIALE JAK2 V617F-POSITIVA E SINDROME MIELODISPLASTICA ASSOCIATA A DEL(5Q) 157
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 152
Identification of SARS-CoV-2 Proteins from Nasopharyngeal Swabs Probed by Multiple Reaction Monitoring Tandem Mass Spectrometry 149
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 146
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 141
FLUORESCENT IN SITU HYBRIDIZATION (FISH) ON PERIPHERAL BLOOD AND BONE MARROW SMARS: 120 MINUTES FOR DETECTION OF PML/RARa FUSION GENE 140
SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods 139
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia. 137
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 136
Molecular Analysis of Cluster Headache 133
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition 132
Coesistence of two distinct cell populations (CD56+Tcr gammadelta+ and CD56+ Tcr gammadelta-) in a case of aggressive CD56+ lymphoma/leukemia 131
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate 129
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-),derived from a single patient with CD56+ non- Hodgkin's lymphoma. 128
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR 125
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia 124
Coexistence of two distinct cell populations (CD56+TcRgd+ and CD56+TcRgd-) in a case of aggressive CD56+ lymphoma/leukemia 124
MiR‐27a downregulates 14‐3‐3θ, RUNX1, AF4, and MLL‐AF4, crucial drivers of blast transformation in t(4;11) leukemia cells 123
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 123
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 122
Bone marrow mesenchymal stem cells as a possible ruxolitinib reservoir in the bone marrow niche 115
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 115
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 114
Molecular monitoring in chronic myeloid leukemia (CML) 113
c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche 111
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia 107
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 106
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 105
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 104
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 104
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 104
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study 101
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 98
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study 98
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 98
Droplet digital pcr for bcr–abl1 monitoring in diagnostic routine: Ready to start? 96
Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in Philadelphia-negative chronic myeloproliferative neoplasm: a case report with literary review 91
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in any high complete molecular response. 90
Wt1 expression levels combined with flow cytometry blast counts for risk stratification of acute myeloid leukemia and myelodysplastic syndromes 89
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 86
Defining low and undetectable levels of disease in chronic myeloid leukemia:progress towards standardisation in Europe 83
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. 80
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 78
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 78
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. 78
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database 77
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. 77
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 73
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale 72
Late appearance of t(8;14) with c-myc rearrangement and disappearance of JH rearrangement leading to aggressive progression in a case of low grade non Hodgkin’s lymphoma” 68
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy 67
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 64
Presence of FLT3 Mutations Does Not Impair Stem Cell Mobilization and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia 56
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype 44
Novel multiplex droplet digital pcr assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical bcr-abl1 transcripts 43
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches 36
CV1 Chimpanzee Adenovirus Efficiently Transduces Mesenchymal Stem and Leukemia Cells: Implications for Cellular Targeting and Vector Tropism 23
Totale 9.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.597
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 0 19 17
2021/2022444 33 4 6 6 6 17 21 17 51 28 140 115
2022/2023497 58 29 19 17 57 53 3 57 71 92 32 9
2023/2024361 17 50 71 17 22 52 12 41 8 9 45 17
2024/20251.931 94 97 15 58 57 81 195 111 167 187 712 157
2025/20263.622 386 282 388 386 634 138 476 216 388 301 27 0
Totale 9.058